UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

Cancer treatment reviews, 2015-12, Vol.41 (10), p.884-892

2015

Volltextzugriff (PDF)

18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival

Cancers, 2020-05, Vol.12 (5), p.1163

2020

Volltextzugriff (PDF)

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

Breast (Edinburgh), 2023-02, Vol.67, p.8-13

2023

Volltextzugriff (PDF)

The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer

Cancers, 2023-04, Vol.15 (9), p.2458

2023

Volltextzugriff (PDF)

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review

Cancers, 2023-09, Vol.15 (19), p.4774

2023

Volltextzugriff (PDF)

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment

Oncotarget, 2015-05, Vol.6 (14), p.12520-12528

2015

Volltextzugriff (PDF)

Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer

Translational lung cancer research, 2016-12, Vol.5 (6), p.610-627

2016

Volltextzugriff (PDF)

Molecular Testing and Treatment Strategies in RET-Rearranged NSCLC Patients: Stay on Target to Look Forward

Journal of Molecular Pathology, 2022-01, Vol.3 (1), p.24-37

2022

Volltextzugriff (PDF)

SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit

Frontiers in oncology, 2020-08, Vol.10, p.1722

2020

Volltextzugriff (PDF)

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Urologic oncology, 2013-04, Vol.31 (3), p.352-358

2013

Volltextzugriff (PDF)

Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey

Lung cancer management, 2017-12, Vol.6 (3), p.93-107

2017

Volltextzugriff (PDF)

Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer

Cells (Basel, Switzerland), 2022-10, Vol.11 (20), p.3226

2022

Volltextzugriff (PDF)

Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center

Exploration of targeted anti-tumor therapy, 2021-01, Vol.2 (5), p.481-489

2021

Volltextzugriff (PDF)

Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies

Journal of clinical oncology, 2014-12, Vol.32 (34), p.3883-3891

2014

Volltextzugriff (PDF)

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis

European urology, 2016-04, Vol.69 (4), p.563-573

2016

Volltextzugriff (PDF)

Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors

Cytokine & growth factor reviews, 2022-10, Vol.67, p.1-10

2022

Volltextzugriff (PDF)

Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario

Critical reviews in oncology/hematology, 2023-04, Vol.184, p.103954-103954, Article 103954

2023

Volltextzugriff (PDF)

Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon

Cancer treatment reviews, 2021-12, Vol.101, p.102308-102308, Article 102308

2021

Volltextzugriff (PDF)

Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer

Cancer treatment reviews, 2016-03, Vol.44, p.61-73

2016

Volltextzugriff (PDF)

Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

Lung cancer (Amsterdam, Netherlands), 2021-07, Vol.157, p.85-91

2021

Volltextzugriff (PDF)

Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules

Journal of thoracic oncology, 2020-10, Vol.15 (10), p.e170-e172

2020

Volltextzugriff (PDF)

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

Translational lung cancer research, 2020-12, Vol.9 (6), p.2674-2685

2020

Volltextzugriff (PDF)

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Critical reviews in oncology/hematology, 2022-04, Vol.172, p.103639-103639, Article 103639

2022

Volltextzugriff (PDF)

Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

Translational cancer research, 2019-03, Vol.8 (Suppl 2), p.S79-S83

2019

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(40)
Tagungsberichte
(1)

Sprache

Englisch
(41)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Oncology
(23)
Humans
(21)
Male
(12)
Aged
(10)
Middle Aged
(8)
Aged, 80 And Over
(7)
Treatment Outcome
(7)
Female
(6)
Immunotherapy
(6)
Lung Cancer
(6)
Prognosis
(6)
Disease-Free Survival
(5)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(5)
Respiratory System
(5)
Cell Biology
(4)
Chemotherapy
(4)
Mutation
(4)
Non-Small Cell Lung Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment

Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer

Molecular Testing and Treatment Strategies in RET-Rearranged NSCLC Patients: Stay on Target to Look Forward

SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit

Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey

Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer

Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center

Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis

Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors

Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario

Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon

Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer

Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?

Suchergebnisse filtern